A differential association of Apolipoprotein E isoforms with the amyloid-β oligomer in solution

Proteins: Structure, Function and Bioinformatics

Volumn 79, Issue 2, 2011, Pages 402-416

  Petrlova, Jitka ^a   Hong, Hyun Seok ^b   Bricarello, Daniel A ^c   Harishchandra, Ghimire ^d   Lorigan, Gary A ^d   Jin, Lee Way ^b   Voss, John C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MIAMI UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Amyloid peptide; ApoE isoforms; Apolipoprotein E; EPR spectroscopy; TOAC spin label

Indexed keywords

2,2,6,6 TETRAMETHYLPIPERIDINE 1 OXYL 4 AMINO 4 CARBOXYLIC ACID; AMYLOID BETA PROTEIN[1-40]; APOLIPOPROTEIN E; CARBOXYLIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CARBOXY TERMINAL SEQUENCE; ELECTRON SPIN RESONANCE; HUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION;

AMYLOID BETA-PEPTIDES; ANIMALS; APOLIPOPROTEINS E; ELECTRON SPIN RESONANCE SPECTROSCOPY; HUMANS; MICE; PROTEIN BINDING; PROTEIN ISOFORMS; SURFACE PLASMON RESONANCE;

EID: 78650792092     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.22891     Document Type: Article

References (60)

1. Gupta V, Narayanaswami V, Budamagunta MS, Yamamato T, Voss JC, Ryan RO. Lipid-induced extension of apolipoprotein E helix 4 correlates with low density lipoprotein receptor binding ability. J Biol Chem 2006; 281: 39294-39299.
2. Hatters DM, Voss JC, Budamagunta MS, Newhouse YN, Weisgraber KH. Insight on the molecular envelope of lipid-bound apolipoprotein E from electron paramagnetic resonance spectroscopy. J Mol Biol 2009; 386: 261-271.
3. Bharadwaj PR, Dubey AK, Masters CL, Martins RN, Macreadie IG. Abeta aggregation and possible implications in Alzheimer's disease pathogenesis. J Cell Mol Med 2009; 13: 412-421.
4. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH. A specific amyloid-β protein assembly in the brain impairs memory. Nature 2006; 440: 352-357.
5. Klein WL, Stine WBJr, Teplow DB. Small assemblies of unmodified amyloid β-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol Aging 2004; 25: 569-580.
6. Weisgraber KH, Mahley RW. Human apolipoprotein E: the Alzheimer's disease connection. FASEB J 1996; 10: 1485-1494.
7. Raber J, Huang Y, Ashford JW. ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol Aging 2004; 25: 641-650.
8. Cedazo-Minguez A, Cowburn RF. Apolipoprotein E: a major piece in the Alzheimer's disease puzzle. J Cell Mol Med 2001; 5: 254-266.
9. Hirsch-Reinshagen V, Wellington CL. Cholesterol metabolism, apolipoprotein E, adenosine triphosphate-binding cassette transporters, and Alzheimer's disease. Curr Opin Lipidol 2007; 18: 325-332.
10. Hatters DM, Peters-Libeu CA, Weisgraber KH. Apolipoprotein E structure: insights into function. Trends Biochem Sci 2006; 31: 445-454.
11. Manelli AM, Stine WB, Van Eldik LJ, LaDu MJ. ApoE and Aβ1-42 interactions: effects of isoform and conformation on structure and function. J Mol Neurosci 2004; 23: 235-246.
12. Tokuda T, Calero M, Matsubara E, Vidal R, Kumar A, Permanne B, Zlokovic B, Smith JD, Ladu MJ, Rostagno A, Frangione B, Ghiso J. Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptides. Biochem J 2000; 348(Pt 2): 359-365.
13. Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M, Schmechel D, Saunders AM, Goldgaber D, Roses AD. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993; 90: 8098-8102.
14. Sanan DA, Weisgraber KH, Russell SJ, Mahley RW, Huang D, Saunders A, Schmechel D, Wisniewski T, Frangione B, Roses AD, Strittmatter WJ. Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest 1994; 94: 860-869.
15. Hatters DM, Zhong N, Rutenber E, Weisgraber KH. Amino-terminal domain stability mediates apolipoprotein E aggregation into neurotoxic fibrils. J Mol Biol 2006; 361: 932-944.
16. Nathan BP, Bellosta S, Sanan DA, Weisgraber KH, Mahley RW, Pitas RE. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science 1994; 264: 850-852.
17. Jordan J, Galindo MF, Miller RJ, Reardon CA, Getz GS, LaDu MJ. Isoform-specific effect of apolipoprotein E on cell survival and beta-amyloid-induced toxicity in rat hippocampal pyramidal neuronal cultures. J Neurosci 1998; 18: 195-204.
18. Carter DB. The interaction of amyloid-β with ApoE. Subcell Biochem 2005; 38: 255-272.
19. Wisniewski T, Castano EM, Golabek A, Vogel T, Frangione B. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J Pathol 1994; 145: 1030-1035.
20. Wisniewski T, Frangione B. Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett 1992; 135: 235-238.
21. Stine WB, Jr., Dahlgren KN, Krafft GA, LaDu MJ. In vitro characterization of conditions for amyloid-β peptide oligomerization and fibrillogenesis. J Biol Chem 2003; 278: 11612-11622.
22. Torok M, Milton S, Kayed R, Wu P, McIntire T, Glabe CG, Langen R. Structural and dynamic features of Alzheimer's Aβ peptide in amyloid fibrils studied by site-directed spin labeling. J Biol Chem 2002; 277: 40810-40815.
23. Petkova AT, Yau WM, Tycko R. Experimental constraints on quaternary structure in Alzheimer's beta-amyloid fibrils. Biochemistry 2006; 45: 498-512.
24. Reddy G, Straub JE, Thirumalai D. Influence of preformed Asp23-Lys28 salt bridge on the conformational fluctuations of monomers and dimers of Aβ peptides with implications for rates of fibril formation. J Phys Chem B 2009; 113: 1162-1172.
25. Tarus B, Straub JE, Thirumalai D. Dynamics of Asp23-Lys28 salt-bridge formation in Abeta10-35 monomers. J Am Chem Soc 2006; 128: 16159-16168.
26. Lazo ND, Grant MA, Condron MC, Rigby AC, Teplow DB. On the nucleation of amyloid beta-protein monomer folding. Protein Sci 2005; 14: 1581-1596.
27. McNulty JC, Millhauser GL. TOAC: the rigid nitroxide side chain. In: Berliner LJ, Eaton SS, Eaton GR, editors. Distance measurements in biological systems by EPR. Volume 19: Biological magnetic resonance. New York: Plenum; 2000. pp 277-307.
28. Baumketner A, Shea JE. The structure of the Alzheimer amyloid beta 10-35 peptide probed through replica-exchange molecular dynamics simulations in explicit solvent. J Mol Biol 2007; 366: 275-285.
29. Bentley NM, Ladu MJ, Rajan C, Getz GS, Reardon CA. Apolipoprotein E structural requirements for the formation of SDS-stable complexes with beta-amyloid-(1-40): the role of salt bridges. Biochem J 2002; 366(Pt 1): 273-279.
30. Marchetto R, Schreier S, Nakaie CR. A novel spin-labeled amino acid derivative for use in peptide synthesis: (9-fluorenylmethyloxycarbonyl)-2, 2, 6, 6-tetramethylpiperidine-N-oxyl-4-amino-4-carboxylic Acid. J Am Chem Soc 1993; 115: 11042-11043.
31. Hong HS, Maezawa I, Yao N, Xu B, Diaz-Avalos R, Rana S, Hua DH, Cheng RH, Lam KS, Jin LW. Combining the rapid MTT formazan exocytosis assay and the MC65 protection assay led to the discovery of carbazole analogs as small molecule inhibitors of Abeta oligomer-induced cytotoxicity. Brain Res 2007; 1130: 223-234.
32. Hess JF, Voss JC, FitzGerald PG. Real-time observation of coiled-coil domains and subunit assembly in intermediate filaments. J Biol Chem 2002; 277: 35516-35522.
33. Wang L, Gill R, Pedersen TL, Higgins LJ, Newman JW, Rutledge JC. Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation. J Lipid Res 2009; 50: 204-213.
34. Lagerstedt JO, Budamagunta MS, Oda MN, Voss JC. Electron paramagnetic resonance spectroscopy of site-directed spin labels reveals the structural heterogeneity in the N-terminal domain of apoA-I in solution. J Biol Chem 2007; 282: 9143-9149.
35. Murphy LR, Matubayasi N, Payne VA, Levy RM. Protein hydration and unfolding-insights from experimental partial specific volumes and unfolded protein models. Fold Des 1998; 3: 105-118.
36. Hornak JP, Moscicki JK, Schneider DJ, Freed JH. Diffusion coefficients in anisotropic fluids by ESR imaging of concentration profiles. J Chem Phys 1986; 84: 3387-3395.
37. Press WW, Teukolsky SA, Vetterling WT, Flannery BP. Numerical recipes in Fortran: the art of scientific computing. New York: Cambridge University Press; 1992. 963 p.
38. Budil DE, Lee S, Saxena S, Freed JH. Nonlinear-least-squares analysis of slow-motion EPR spectra in one and two dimensions using a modified Levenberg-Marquardt algorithm. J Magn Reson Ser A 1996; 120: 155-189.
39. Schneider DJ, Freed JH. Calculating slow motional magnetic resonance spectra: a users's guide. In: Berliner LJ, Reuben J, editors. Spin labeling: theory and applications, Vol. 8: Biological magnetic resonance. New York: Plenum; 1989. pp 1-76.
40. Sato K, Higuchi M, Iwata N, Saido TC, Sasamoto K. Fluoro-substituted and 13C-labeled styrylbenzene derivatives for detecting brain amyloid plaques. Eur J Med Chem 2004; 39: 573-578.
41. Pietrasanta LI, Thrower D, Hsieh W, Rao S, Stemmann O, Lechner J, Carbon J, Hansma H. Probing the Saccharomyces cerevisiae centromeric DNA (CEN DNA)-binding factor 3 (CBF3) kinetochore complex by using atomic force microscopy. Proc Natl Acad Sci USA 1999; 96: 3757-3762.
42. Lam AR, Teplow DB, Stanley HE, Urbanc B. Effects of the Arctic (E22->G) mutation on amyloid β-protein folding: discrete molecular dynamics study. J Am Chem Soc 2008; 130: 17413-17422.
43. Liu FF, Ji L, Dong XY, Sun Y. Molecular insight into the inhibition effect of trehalose on the nucleation and elongation of amyloid β-peptide oligomers. J Phys Chem B 2009; 113: 11320-11329.
44. Hong HS, Maezawa I, Budamagunta M, Rana S, Shi A, Vassar R, Liu R, Lam KS, Cheng RH, Hua DH, Voss JC, Jin LW. Candidate anti-Aβ fluorene compounds selected from analogs of amyloid imaging agents. Neurobiol Aging 2010; 31: 1690-1699.
45. Reinhard C, Hebert SS, De Strooper B. The amyloid-β precursor protein: integrating structure with biological function. EMBO J 2005; 24: 3996-4006.
46. Tetali SD, Budamagunta MS, Voss JC, Rutledge JC. C-terminal interactions of apolipoprotein E4 respond to the postprandial state. J Lipid Res 2006; 47: 1358-1365.
47. Hatters DM, Budamagunta MS, Voss JC, Weisgraber KH. Modulation of apolipoprotein E structure by domain interaction: differences in lipid-bound and lipid-free forms. J Biol Chem 2005; 280: 34288-34295.
48. Zhang Y, Vasudevan S, Sojitrawala R, Zhao W, Cui C, Xu C, Fan D, Newhouse Y, Balestra R, Jerome WG, Weisgraber K, Li Q, Wang J. A monomeric, biologically active, full-length human apolipoprotein E. Biochemistry 2007; 46: 10722-10732.
49. Fan D, Li Q, Korando L, Jerome WG, Wang J. A monomeric human apolipoprotein E carboxyl-terminal domain. Biochemistry 2004; 43: 5055-5064.
50. Piliarik M, Vaisocherova H, Homola J. Surface plasmon resonance biosensing. Methods Mol Biol 2009; 503: 65-88.
51. Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D, Paul SM. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2000; 97: 2892-2897.
52. LaDu MJ, Falduto MT, Manelli AM, Reardon CA, Getz GS, Frail DE. Isoform-specific binding of apolipoprotein E to β-amyloid. J Biol Chem 1994; 269: 23403-23406.
53. Zhou Z, Relkin N, Ghiso J, Smith JD, Gandy S. Human cerebrospinal fluid apolipoprotein E isoforms are apparently inefficient at complexing with synthetic Alzheimer's amyloid-[β] peptide (A[β] 1-40) in vitro. Mol Med 2002; 8: 376-381.
54. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003; 300: 486-489.
55. Murakami K, Hara H, Masuda Y, Ohigashi H, Irie K. Distance measurement between Tyr10 and Met35 in amyloid beta by site-directed spin-labeling ESR spectroscopy: implications for the stronger neurotoxicity of Abeta42 than Abeta40. Chembiochem 2007; 8: 2308-2314.
56. Crisma M, Deschamps JR, George C, Flippen-Anderson JL, Kaptein B, Broxterman QB, Moretto A, Oancea S, Jost M, Formaggio F, Toniolo C. A topographically and conformationally constrained, spin-labeled, alpha-amino acid: crystallographic characterization in peptides. J Pept Res 2005; 65: 564-579.
57. Sgourakis NG, Yan Y, McCallum SA, Wang C, Garcia AE. The Alzheimer's peptides Aβ40 and 42 adopt distinct conformations in water: a combined MD/NMR study. J Mol Biol 2007; 368: 1448-1457.
58. Zhang S, Iwata K, Lachenmann MJ, Peng JW, Li S, Stimson ER, Lu Y, Felix AM, Maggio JE, Lee JP. The Alzheimer's peptide a beta adopts a collapsed coil structure in water. J Struct Biol 2000; 130: 130-141.
59. Morrow JA, Segall ML, Lund-Katz S, Phillips MC, Knapp M, Rupp B, Weisgraber KH. Differences in stability among the human apolipoprotein E isoforms determined by the amino-terminal domain. Biochemistry 2000; 39: 11657-11666.
60. Krafft GA, Klein WL. ADDLs and the signaling web that leads to Alzheimer's disease. Neuropharmacology 2010; 59: 230-242.